Weindel K, Moringlane J R, Marmé D, Weich H A
Institute of Molecular Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Neurosurgery. 1994 Sep;35(3):439-48; discussion 448-9. doi: 10.1227/00006123-199409000-00012.
In primary malignant brain tumors increased vascularity and marked edema strongly suggest a possible role of the vascular endothelial growth factor/vascular permeability factor (VEGF/VPF). This was confirmed by earlier in situ hybridization studies, by analysis of the expression of the mitogen in different subsets of glioblastoma cells, and by the fact that the VEGF/VPF receptor flt-1 (fms-like tyrosine kinase) is up-regulated in tumor cells in vivo. To assess and quantify the expression of the VEGF/VPF gene and of the receptor gene, 26 surgical specimens of brain tumor tissue from 24 patients were analyzed. In most malignant gliomas, the expression level of the VEGF/VPF gene is elevated and can be increased up to 20- to 50-fold in comparison with low-grade tumors. Using polymerase chain reaction-based amplification, it could be shown that the messenger RNAs of three different VEGF/VPF forms are synthesized in tumor tissue samples. Northern blot studies revealed that in some samples a significant expression of the gene coding for placenta growth factor, a growth factor closely related to VEGF/VPF, was observed. In addition, using a radioreceptor assay it was possible to detect high VEGF/VPF-like activity in the cyst fluids of brain tumors, indicating the accumulation of the mitogen and permeability factor in brain tumor cysts. Further investigations revealed that astrocytoma and glioblastoma cells in culture express the VEGF/VPF gene and secrete the VEGF/VPF protein, whereas gene expression of the two known VEGF/VPF receptors, kinase insert domain-containing receptor and flt-1, could not be detected. These data support previous reports, which stated that VEGF/VPF acts as a paracrine growth and permeability factor in brain tumors and may contribute to tumor growth by initiating tumor angiogenesis.
在原发性恶性脑肿瘤中,血管增多和明显水肿强烈提示血管内皮生长因子/血管通透因子(VEGF/VPF)可能发挥作用。早期的原位杂交研究、对不同亚群胶质母细胞瘤细胞中促有丝分裂原表达的分析以及VEGF/VPF受体flt-1(fms样酪氨酸激酶)在体内肿瘤细胞中上调的事实均证实了这一点。为了评估和定量VEGF/VPF基因及受体基因的表达,分析了来自24例患者的26份脑肿瘤组织手术标本。在大多数恶性胶质瘤中,VEGF/VPF基因的表达水平升高,与低级别肿瘤相比,其表达水平可增加20至50倍。利用基于聚合酶链反应的扩增技术,可以证明肿瘤组织样本中合成了三种不同形式的VEGF/VPF信使核糖核酸。Northern印迹研究显示,在一些样本中观察到了与VEGF/VPF密切相关的生长因子——胎盘生长因子编码基因的显著表达。此外,使用放射受体测定法能够检测到脑肿瘤囊液中具有高VEGF/VPF样活性,这表明促有丝分裂原和通透因子在脑肿瘤囊肿中蓄积。进一步研究发现,培养的星形细胞瘤和胶质母细胞瘤细胞表达VEGF/VPF基因并分泌VEGF/VPF蛋白,而未检测到两种已知的VEGF/VPF受体——激酶插入结构域受体和flt-1的基因表达。这些数据支持了先前的报道,即VEGF/VPF在脑肿瘤中作为旁分泌生长和通透因子发挥作用,可能通过启动肿瘤血管生成促进肿瘤生长。